Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. Carneiro BA, et al. Among authors: robinson rr. Neurooncol Adv. 2022 Dec 21;5(1):vdac183. doi: 10.1093/noajnl/vdac183. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36814898 Free PMC article.
The legacy of predator threat shapes prey foraging behaviour.
Des Roches S, Robinson RR, Kinnison MT, Palkovacs EP. Des Roches S, et al. Among authors: robinson rr. Oecologia. 2022 Jan;198(1):79-89. doi: 10.1007/s00442-021-05073-9. Epub 2021 Nov 24. Oecologia. 2022. PMID: 34817645
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Kappos L, Cohan S, Arnold DL, Robinson RR, Holman J, Fam S, Parks B, Xiao S, Castro-Borrero W. Kappos L, et al. Among authors: robinson rr. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286420987941. doi: 10.1177/1756286420987941. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33737954 Free PMC article.
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Gold R, et al. Among authors: robinson rr. J Neurol. 2020 Oct;267(10):2851-2864. doi: 10.1007/s00415-020-09835-y. Epub 2020 May 25. J Neurol. 2020. PMID: 32451615 Free PMC article. Clinical Trial.
The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
Ganguly B, Balasa B, Efros L, Hinton PR, Hartman S, Thakur A, Xiong JM, Schmidt B, Robinson RR, Sornasse T, Vexler V, Sheridan JP. Ganguly B, et al. Among authors: robinson rr. MAbs. 2016 Oct;8(7):1417-1424. doi: 10.1080/19420862.2016.1207031. Epub 2016 Jul 1. MAbs. 2016. PMID: 27367933 Free PMC article.
139 results